{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T03:23:07Z","timestamp":1772940187315,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"DOI":"10.1007\/s00432-026-06425-9","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T10:09:40Z","timestamp":1772878180000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hormonal management after risk-reducing surgery in BRCA-mutated triple-negative breast cancer survivors"],"prefix":"10.1007","volume":"152","author":[{"given":"Inna","family":"J\u00f6rg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Chronas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,7]]},"reference":[{"key":"6425_CR1","unstructured":"Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie (AGO). Diagnostik und Therapie des Mammakarzinoms der Frau \u2013 Empfehlungen 2023. https:\/\/www.ago-online.de"},{"issue":"9382","key":"6425_CR2","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/S0140-6736(03)14065-2","volume":"362","author":"V Beral","year":"2003","unstructured":"Beral V, Million Women Study Collaborators (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362(9382):419\u2013427. https:\/\/doi.org\/10.1016\/S0140-6736(03)14065-2","journal-title":"Lancet"},{"issue":"6","key":"6425_CR3","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1002\/jbmr.3984","volume":"35","author":"EK Bjelland","year":"2020","unstructured":"Bjelland EK, Hofvind S, Byberg L, Eskild A (2020) Menopause before age 40 is associated with increased risk of fracture: a population-based cohort study. J Bone Miner Res 35(6):1022\u20131030","journal-title":"J Bone Miner Res"},{"issue":"12","key":"6425_CR4","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","volume":"31","author":"R Coleman","year":"2020","unstructured":"Coleman R, Hadji P, Body JJ et al (2020) Bone health in cancer: ESMO Clinical Practice Guidelines. Ann Oncol 31(12):1650\u20131663","journal-title":"Ann Oncol"},{"issue":"3","key":"6425_CR5","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1080\/13697137.2023.2189583","volume":"26","author":"H Depypere","year":"2023","unstructured":"Depypere H (2023) Treatment of women with BRCA mutation. Climacteric 26(3):235\u2013239. https:\/\/doi.org\/10.1080\/13697137.2023.2189583","journal-title":"Climacteric"},{"issue":"9","key":"6425_CR6","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1001\/jama.2010.1237","volume":"304","author":"SM Domchek","year":"2010","unstructured":"Domchek SM, Friebel TM, Singer CF et al (2010) Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304(9):967\u2013975","journal-title":"JAMA"},{"key":"6425_CR7","doi-asserted-by":"publisher","unstructured":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2015) Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 386(10001):1353\u20131361. https:\/\/doi.org\/10.1016\/S0140-6736(15)60908-4. Epub 2015 Jul 23. Erratum in: Lancet. 2016 Jan 2;387(10013):30. Erratum in: Lancet. 2017 Jun 24;389(10088):2472. https:\/\/doi.org\/10.1016\/S0140-6736(15)60908-4. PMID: 26211824","DOI":"10.1016\/S0140-6736(15)60908-4"},{"key":"6425_CR8","doi-asserted-by":"crossref","unstructured":"Eisen A, Lubinski J, Klijn JG, Moller P, Lynch HT, Offit K et al (2008) Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst 100(19):1361\u20131367","DOI":"10.1093\/jnci\/djn313"},{"issue":"25","key":"6425_CR9","doi-asserted-by":"publisher","first-page":"e506","DOI":"10.1161\/CIR.0000000000000912","volume":"142","author":"SR El Khoudary","year":"2020","unstructured":"El Khoudary SR, Aggarwal B, Beckie TM et al (2020) Menopause transition and cardiovascular disease risk: implications for timing of early prevention. Circulation 142(25):e506\u2013e532","journal-title":"Circulation"},{"issue":"7","key":"6425_CR10","first-page":"e93","volume":"33","author":"ESMO Guidelines Committee","year":"2022","unstructured":"ESMO Guidelines Committee (2022) Hereditary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 33(7):e93\u2013e105","journal-title":"Ann Oncol"},{"issue":"1","key":"6425_CR11","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejca.2012.07.003","volume":"49","author":"M Fahl\u00e9n","year":"2013","unstructured":"Fahl\u00e9n M, Fornander T, Johansson H, Johansson U, Rutqvist LE, Wilking N, von Schoultz E (2013) Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur J Cancer 49(1):52\u201359. https:\/\/doi.org\/10.1016\/j.ejca.2012.07.003","journal-title":"Eur J Cancer"},{"issue":"7","key":"6425_CR12","first-page":"516","volume":"105","author":"M Fahlen","year":"2013","unstructured":"Fahlen M, Fornander T, Johansson H et al (2013) Hormone replacement therapy after breast cancer: 10-year follow-up of the Stockholm randomized trial. J Natl Cancer Inst 105(7):516\u2013525","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"6425_CR13","first-page":"350","volume":"30","author":"R Farrell","year":"2021","unstructured":"Farrell R (2021) Vaginal estrogen preparations: a review of safety and efficacy for the treatment of vulvovaginal atrophy. J Womens Health (Larchmt) 30(3):350\u2013356","journal-title":"J Womens Health (Larchmt)"},{"issue":"1","key":"6425_CR14","first-page":"13","volume":"24","author":"J Furlanetto","year":"2021","unstructured":"Furlanetto J, Garibotti G, Della Corte L et al (2021) Hormone therapy in breast cancer survivors: a systematic review of safety and guidelines. Climacteric 24(1):13\u201323","journal-title":"Climacteric"},{"issue":"1","key":"6425_CR16","first-page":"151","volume":"15","author":"MT Hannan","year":"2000","unstructured":"Hannan MT, Felson DT, Dawson-Hughes B, Tucker KL, Cupples LA, Wilson PW et al (2000) Risk of vertebral fracture in women: the role of low bone mineral density and menopausal status. J Bone Miner Res 15(1):151\u2013157","journal-title":"J Bone Miner Res"},{"issue":"9407","key":"6425_CR17","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S0140-6736(04)15493-7","volume":"363","author":"L Holmberg","year":"2004","unstructured":"Holmberg L (2004) HABITS Steering and Data Monitoring Committees. HABITS (hormonal replacement therapy after breast cancer\u2014is it safe?), a randomised comparison: trial stopped. Lancet 363(9407):453\u2013455","journal-title":"Lancet"},{"issue":"2","key":"6425_CR18","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S1470-2045(08)70341-3","volume":"10","author":"P Kenemans","year":"2009","unstructured":"Kenemans P, Bundred NJ, Foidart JM, Kubista E, von Schoultz B, Sismondi P et al (2009a) Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a randomised, double-blind, placebo-controlled trial. Lancet Oncol 10(2):135-146","journal-title":"Lancet Oncol"},{"issue":"2","key":"6425_CR19","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S1470-2045(08)70341-3","volume":"10","author":"P Kenemans","year":"2009","unstructured":"Kenemans P, Bundred NJ, Foidart JM et al (2009b) Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a randomised, double-blind, placebo-controlled trial. Lancet Oncol 10(2):135\u2013146","journal-title":"Lancet Oncol"},{"issue":"7","key":"6425_CR20","first-page":"746","volume":"316","author":"J Kotsopoulos","year":"2016","unstructured":"Kotsopoulos J, Huzarski T, Gronwald J, Singer CF, Moller P, Lynch HT et al (2016) Hormone replacement therapy after oophorectomy and breast cancer risk among BRCA1 mutation carriers. JAMA 316(7):746\u2013754","journal-title":"JAMA"},{"issue":"5","key":"6425_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2407","volume":"11","author":"CI Li","year":"2009","unstructured":"Li CI, Daling JR, Porter PL, Tang MT, Malone KE (2009) Risk of contralateral breast cancer in women with ductal carcinoma in situ. Breast Cancer Res 11(5):R76. https:\/\/doi.org\/10.1186\/bcr2407","journal-title":"Breast Cancer Res"},{"issue":"4","key":"6425_CR22","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1200\/JCO.2009.24.5647","volume":"28","author":"CL Loprinzi","year":"2010","unstructured":"Loprinzi CL, Qin R, Balcueva EP et al (2010) Phase III randomized, placebo-controlled trial of pregabalin for the treatment of hot flashes. J Clin Oncol 28(4):641\u2013647","journal-title":"J Clin Oncol"},{"issue":"1","key":"6425_CR23","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.3802\/jgo.2020.31.e6","volume":"31","author":"C Marchetti","year":"2020","unstructured":"Marchetti C, De Felice F, Palaia I, Perniola G, Musella A, Muzii L et al (2020) Hormone replacement therapy and risk of breast cancer in BRCA mutation carriers: a systematic review and meta-analysis. J Gynecol Oncol 31(1):e6","journal-title":"J Gynecol Oncol"},{"issue":"1","key":"6425_CR25","first-page":"35","volume":"5","author":"AO Mueck","year":"2002","unstructured":"Mueck AO, Seeger H, Wallwiener D (2002) Hormone replacement therapy after treatment of breast cancer: the state of the art. Climacteric 5(1):35\u201342","journal-title":"Climacteric"},{"key":"6425_CR26","unstructured":"National Comprehensive Cancer Network (NCCN) (2022) Genetic\/familial high-risk assessment: breast, ovarian, and pancreatic. Version 1.2022. https:\/\/www.nccn.org"},{"issue":"14","key":"6425_CR27","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1001\/archinte.166.14.1453","volume":"166","author":"A Nedrow","year":"2006","unstructured":"Nedrow A, Miller J, Walker M et al (2006) Complementary and alternative therapies for the management of menopause-related symptoms: a systematic evidence review. Arch Intern Med 166(14):1453\u20131465","journal-title":"Arch Intern Med"},{"issue":"9614","key":"6425_CR28","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0140-6736(08)60346-3","volume":"371","author":"HD Nelson","year":"2008","unstructured":"Nelson HD (2008) Menopause. Lancet 371(9614):760\u2013770","journal-title":"Lancet"},{"key":"6425_CR29","unstructured":"NHS Vale of York Clinical Commissioning Group (2021) Primary and recurrent breast cancer: hormonal receptor status variation and mplications"},{"issue":"7","key":"6425_CR30","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1097\/GME.0000000000002028","volume":"29","author":"North American Menopause Society (NAMS)","year":"2022","unstructured":"North American Menopause Society (NAMS) (2022) 2022 hormone therapy position statement. Menopause 29(7):767\u2013794","journal-title":"Menopause"},{"key":"6425_CR31","unstructured":"Elinzanetant meets all primary and secondary endpoints in phase III study OASIS 4 for treatment of moderate to severe vasomotor symptoms caused by breast cancer treatments. January 9, 2025. Accessed January 9, 2025."},{"issue":"5","key":"6425_CR32","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1097\/AOG.0b013e3181a11c64","volume":"113","author":"WH Parker","year":"2009","unstructured":"Parker WH, Broder MS, Chang E, Feskanich D, Farquhar C, Liu Z et al (2009) Ovarian conservation at the time of hysterectomy and long-term health outcomes in the Nurses\u2019 Health Study. Obstet Gynecol 113(5):1027\u20131037","journal-title":"Obstet Gynecol"},{"issue":"31","key":"6425_CR33","doi-asserted-by":"publisher","first-page":"7804","DOI":"10.1200\/JCO.2004.00.8151","volume":"23","author":"TR Rebbeck","year":"2005","unstructured":"Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB et al (2005) Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 23(31):7804\u20137810","journal-title":"J Clin Oncol"},{"issue":"2","key":"6425_CR34","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/jnci\/djn442","volume":"101","author":"TR Rebbeck","year":"2009","unstructured":"Rebbeck TR, Kauff ND, Domchek SM (2009) Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 101(2):80\u201387","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"6425_CR35","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1258\/mi.2008.008016","volume":"14","author":"LT Shuster","year":"2008","unstructured":"Shuster LT, Gostout BS, Grossardt BR, Rocca WA (2008) Prophylactic oophorectomy in premenopausal women and long-term health risks. Menopause Int 14(3):111\u2013116","journal-title":"Menopause Int"},{"issue":"2","key":"6425_CR36","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.maturitas.2009.08.003","volume":"65","author":"LT Shuster","year":"2010","unstructured":"Shuster LT, Rhodes DJ, Gostout BS, Grossardt BR, Rocca WA (2010) Premature menopause or early menopause: long-term health consequences. Maturitas 65(2):161\u2013166","journal-title":"Maturitas"},{"issue":"2","key":"6425_CR37","first-page":"221","volume":"141","author":"JA Simon","year":"2023","unstructured":"Simon JA, Lin VH, Radovich C et al (2023) Fezolinetant for treatment of moderate to severe vasomotor symptoms associated with menopause: results from the SKYLIGHT 2 trial. Obstet Gynecol 141(2):221\u2013230","journal-title":"Obstet Gynecol"},{"issue":"11","key":"6425_CR38","doi-asserted-by":"publisher","first-page":"3975","DOI":"10.1210\/jc.2015-2236","volume":"100","author":"CA Stuenkel","year":"2015","unstructured":"Stuenkel CA, Davis SR, Gompel A, Lumsden MA, Murad MH, Pinkerton JV et al (2015) Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 100(11):3975\u20134011","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"6425_CR39","first-page":"389","volume":"43","author":"The Society of Obstetricians and Gynaecologists of Canada (SOGC)","year":"2021","unstructured":"The Society of Obstetricians and Gynaecologists of Canada (SOGC) (2021) Menopause and breast cancer: clinical practice guideline. J Obstet Gynaecol Can 43(4):389\u2013402","journal-title":"J Obstet Gynaecol Can"},{"issue":"1","key":"6425_CR40","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1586\/14737140.9.1.51","volume":"9","author":"VG Vogel","year":"2009","unstructured":"Vogel VG (2009) The NSABP study of tamoxifen and raloxifene (STAR) trial. Expert Rev Anticancer Ther 9(1):51\u201360","journal-title":"Expert Rev Anticancer Ther"},{"issue":"6","key":"6425_CR41","first-page":"571","volume":"81","author":"A W\u00f6ckel","year":"2021","unstructured":"W\u00f6ckel A, St\u00fcber T, Hadji P, Kreienberg R, Tesch H (2021) Heredit\u00e4res Mammakarzinom: Empfehlungen der S3-Leitlinie Mammakarzinom zur Diagnostik, Beratung und Therapie. Geburtshilfe Frauenheilkd 81(6):571\u2013585","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"11","key":"6425_CR42","doi-asserted-by":"publisher","first-page":"e553","DOI":"10.1016\/S2468-2667(19)30155-0","volume":"4","author":"D Zhu","year":"2019","unstructured":"Zhu D, Chung HF, Dobson AJ, Pandeya N, Avis NE, Crawford SL et al (2019) Age at natural menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data. Lancet Public Health 4(11):e553\u2013e564","journal-title":"Lancet Public Health"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06425-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-026-06425-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06425-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T10:09:42Z","timestamp":1772878182000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-026-06425-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,7]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["6425"],"URL":"https:\/\/doi.org\/10.1007\/s00432-026-06425-9","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,7]]},"assertion":[{"value":"11 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"60"}}